Flexion Therapeutics (NASDAQ:FLXN) announced its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.01) by $0.01, Fidelity Earnings reports. Flexion Therapeutics had a negative return on equity of 175.29% and a negative net margin of 368.31%. The company had revenue of $21.79 million for the quarter, compared to analyst estimates of $18.85 million.
Shares of FLXN stock traded down $0.69 during midday trading on Friday, reaching $16.43. 1,132,400 shares of the company traded hands, compared to its average volume of 622,178. Flexion Therapeutics has a 1-year low of $8.76 and a 1-year high of $17.82. The firm’s 50 day simple moving average is $14.85 and its two-hundred day simple moving average is $12.36. The firm has a market cap of $655.05 million, a PE ratio of -3.66 and a beta of 1.38. The company has a debt-to-equity ratio of 3.95, a current ratio of 7.80 and a quick ratio of 7.33.
FLXN has been the subject of a number of research reports. ValuEngine downgraded shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 8th. BidaskClub upgraded shares of Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 5th. Finally, Northland Securities set a $20.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 10th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Flexion Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $23.57.
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Further Reading: What are Institutional Investors?
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.